Edition:
United Kingdom

Ocular Therapeutix Inc (OCUL.OQ)

OCUL.OQ on NASDAQ Stock Exchange Global Market

6.48USD
3:42pm BST
Change (% chg)

$0.00 (+0.00%)
Prev Close
$6.48
Open
$6.44
Day's High
$6.49
Day's Low
$6.42
Volume
11,772
Avg. Vol
123,981
52-wk High
$11.79
52-wk Low
$3.30

Select another date:

Thu, Mar 8 2018

BRIEF-Ocular Therapeutix Reports Q4 Loss Per Share $0.44

* OCULAR THERAPEUTIX™ REPORTS FOURTH QUARTER AND YEAR END 2017 FINANCIAL RESULTS AND BUSINESS UPDATE

BRIEF-Summer Road Reports 8.4 Pct Passive Stake In Ocular Therapeutix

* SUMMER ROAD LLC REPORTS 8.4 PERCENT PASSIVE STAKE IN OCULAR THERAPEUTIX INC AS OF JANUARY 29, 2018 - SEC FILING‍​ Source text: (http://bit.ly/2BjW1c4) Further company coverage:

BRIEF-Ocular TherapeutixTM Announces Public Offering Of 6.50 Mln Common Shares

* OCULAR THERAPEUTIXTM ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

BRIEF-Ocular Therapeutix Announces Proposed Public Offering Of Common Stock

* OCULAR THERAPEUTIX™ ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

BRIEF-Ocular Therapeutix Announces Kevin Hanley As Senior Vice President Technical Operations

* OCULAR THERAPEUTIX ANNOUNCES KEVIN HANLEY AS SENIOR VICE PRESIDENT, TECHNICAL OPERATIONS AND NAYMISHA PATEL AS VICE PRESIDENT OF QUALITY Source text for Eikon: Further company coverage:

Ocular Therapeutix gets subpoena from SEC over eye pain drug

Ocular Therapeutix Inc said on Friday the U.S. Securities and Exchange Commission (SEC) had issued a subpoena seeking information about the company's eye-pain drug Dextenza.

BRIEF-Ocular Therapeutix Provides Legal Update

* OCULAR THERAPEUTIX INC - ON DEC. 21, CO WAS SERVED WITH A NEW DERIVATIVE COMPLAINT

Ocular Therapeutix gets subpoena from SEC over eye pain drug

Dec 22 Ocular Therapeutix Inc said on Friday the U.S. Securities and Exchange Commission (SEC) had issued a subpoena seeking information about the company's eye-pain drug Dextenza.

BRIEF-Ocular Therapeutix posts Q3 loss per share $0.54

* Ocular Therapeutix reports third quarter 2017 financial results and provides corporate update

Select another date: